Loading
Loading
Bremelanotide · melanocortin-receptor research peptide
A cyclic heptapeptide melanocortin receptor agonist. Originally developed from melanotan-II, PT-141 is the active research analog approved in some jurisdictions for hypoactive sexual desire disorder under the name bremelanotide.
PT-141 (bremelanotide) is a cyclic melanocortin-receptor agonist and a worked example of a research peptide that progressed through Phase-3 trials to FDA approval.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that activates melanocortin receptors MC3R and MC4R. Research and Phase-3 clinical data led to its 2019 FDA approval (under the trade name Vyleesi) for premenopausal hypoactive sexual desire disorder.
CoA available on request
Every PT-141 lot is independently tested in Dubai or the UK and documented with a signed Certificate of Analysis. To review the CoA for a specific lot, email support@caesarbiomedical.com with the lot number, or look it up on our verification page.
For laboratory research use only.
Have a question about a compound, its mechanism, or a lab report? Message us on WhatsApp and a member of the research team will reply - no forms, no sales script.
The research letter
One email per month. Citations included. Zero filler.